8-K: Modular Medical Announces $10 Million Public Offering of Common Stock

Modular Medical has entered into an underwriting agreement for a public offering of 9,090,910 shares of common stock at $1.10 per share, with an option for the underwriter to purchase additional shares.

Summary

• Modular Medical, Inc. has agreed to sell 9,090,910 shares of common stock in a public offering.
• The offering price is set at $1.10 per share.
• The company has granted the underwriter a 30-day option to purchase an additional 1,321,989 shares.
• The gross proceeds from the offering are estimated to be $10 million, before deducting underwriting discounts, commissions, and offering expenses.
• The offering is expected to close around February 21, 2024, subject to customary closing conditions.
• The company intends to use the net proceeds for operations, working capital, and general corporate purposes, including capital expenditures.

Sentiment

Score: 7

Explanation: The document is generally positive, indicating a successful capital raise for the company. However, there are inherent risks and restrictions associated with the offering, which temper the overall sentiment.

Positives

• The offering provides Modular Medical with $10 million in gross proceeds to fund operations and working capital.
• The company has secured an underwriter for the offering, Titan Partners Group LLC.
• Existing institutional investors, including the CEO and a board member, are participating in the offering.

Negatives

• The offering will dilute existing shareholders' ownership.
• The company is subject to restrictions on issuing new shares and engaging in certain transactions for a year after closing.

Risks

• The offering is subject to market conditions and may not be completed.
• The company's future performance is subject to various risks, including the development and market acceptance of its products.
• The company's ability to obtain regulatory clearance for its MODD1 product is not guaranteed.
• The company's ability to manufacture its products at high volumes is not guaranteed.

Future Outlook

The company intends to use the net proceeds from the offering to fund operations, working capital, and general corporate purposes, including capital expenditures. The company is also subject to certain restrictions on issuing new shares and engaging in certain transactions for a year after closing.

Management Comments

• Modular Medical is a development-stage medical device company that intends to launch the next generation of insulin delivery technology.
• The company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn.
• The company's mission is to improve access to the highest standard of glycemic control for people with diabetes.

Industry Context

This offering is part of Modular Medical's strategy to raise capital to support the development and launch of its insulin delivery technology. The company is operating in the competitive medical device industry, specifically in the diabetes care market, where innovation and affordability are key factors.

Comparison to Industry Standards

• The offering is a common method for development-stage medical device companies to raise capital.
• The lock-up agreements are standard practice to ensure stability after an offering.
• The restrictions on future equity issuances are also common to protect investors from dilution.
• Tandem Diabetes, founded by Modular Medical's founder, is a comparable company in the insulin pump market, and its performance and market reception could be a benchmark for Modular Medical.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• The company will have additional capital to fund its operations and development.
• The company's employees will benefit from the increased financial stability of the company.
• Customers may benefit from the development and launch of new insulin delivery technology.

Next Steps

• The company will proceed with the closing of the offering, expected on or about February 21, 2024.
• The company will use the net proceeds for operations, working capital, and general corporate purposes.
• The company will continue to develop and seek regulatory clearance for its MODD1 product.

Key Dates

Keywords

public offering, common stock, underwriting agreement, capital raise, insulin pump, medical device, MODD, Titan Partners Group, lock-up agreement, variable rate transaction